Drug combination for stomach cancer with abdominal spread
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of chemotherapy drugs (LM-302, S-1, and paclitaxel) with or without an immune-boosting drug (cadonilimab) for gastric cancer that has spread to the abdominal lining. The goal is to shrink tumors and improve survival in patients whose cancer cells show a specific protein marker called Claudin 18.2.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Confirmed gastric or gastroesophageal junction cancer (no prior surgery on primary tumor or metastases)
- Cancer has spread to the abdominal lining (peritoneal metastases), confirmed by laparoscopy
- Claudin 18.2 protein present on your cancer cells (at least 25% of cells, moderate to strong staining)
- Overall health status allowing normal activities with some limitations (ECOG score 0–1)
- Expected to live longer than 3 months
- Adequate bone marrow, liver, and kidney function based on blood and lab tests
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (given through a vein and a pill) plus a chemotherapy infusion directly into your belly for stomach cancer that has spread to the lining of the abdomen. It specifically looks at a marker called Claudin 18.2 to see if this treatment works better for people with that marker.
This trial tests whether giving immunotherapy and chemotherapy drugs before surgery can help treat stomach cancer that has a specific protein marker (claudin 18.2). The goal is to shrink the tumor and improve outcomes for patients whose cancer can be surgically removed.
This study tests a combination of three drugs (LM-302, Candonilimab, and Capecitabine) as the first treatment for advanced stomach cancer that has a specific protein (Claudin 18.2). It aims to see if the combination shrinks tumors and is safe.
This trial tests a new immunotherapy drug (SHR-1701) combined with chemotherapy for people with stomach or gastroesophageal junction cancer that has spread to the lining of the abdomen (peritoneal metastasis) but not to other organs like the liver or lungs. The goal is to see if this combination can help shrink or control the cancer before any surgery.
This trial tests a combination of three drugs—cadonilimab, fruquintinib, and albumin-bound paclitaxel—as a second treatment for advanced stomach cancer. It may be an option if your first treatment stopped working and you have not had certain types of prior therapy.
This trial tests a combination of two drugs, nab-paclitaxel and cadonilimab, as a second treatment for advanced stomach cancer that has spread to the belly lining. It may be an option if you haven't had any prior cancer therapy.
Hear when a new Gastric Cancer Stage IV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.